rexahn
pharmaceuticals
announces
stockholder
approval
proposals
required
merger
ocuphire
pharma
rockville
globe
newswire
rexahn
pharmaceuticals
nasdaq
rexn
rexahn
announced
today
special
meeting
stockholders
held
november
rexahn
stockholders
approved
proposals
presented
including
issuance
shares
rexahn
common
stock
pursuant
agreement
plan
merger
reorganization
dated
june
amended
among
rexahn
razor
merger
sub
ocuphire
pharma
ocuphire
change
control
rexahn
resulting
merger
ii
reverse
stock
split
rexahn
common
stock
ratio
one
new
share
every
shares
outstanding
final
ratio
approved
rexahn
board
directors
iii
changing
name
rexahn
rexahn
pharmaceuticals
ocuphire
pharma
iv
adoption
ocuphire
pharma
equity
incentive
plan
v
issuance
shares
rexahn
common
stock
upon
exercise
warrants
issued
financing
issuance
additional
shares
rexahn
common
stock
may
issued
following
closing
financing
appreciate
participation
support
stockholders
regarding
upcoming
merger
transaction
ocuphire
commented
douglas
swirsky
president
ceo
rexahn
ocuphire
board
directors
president
ceo
mina
sooch
well
positioned
guide
combined
company
forward
exciting
pipeline
ophthalmic
therapeutic
candidates
multiple
potential
value
inflection
points
recent
approvals
stockholders
rexahn
ocuphire
previously
announced
unanimous
approval
boards
directors
rexahn
ocuphire
merger
expected
consummated
november
subject
satisfaction
certain
closing
conditions
connection
closing
merger
rexahn
change
name
ocuphire
pharma
combined
company
shares
expected
commence
trading
nasdaq
capital
market
symbol
ocup
final
voting
results
rexahn
special
meeting
stockholders
filed
securities
exchange
commission
sec
current
report
form
ocuphire
pharma
ocuphire
ophthalmic
biopharmaceutical
company
focused
developing
commercializing
therapies
treatment
several
eye
disorders
ocuphire
pipeline
currently
includes
two
product
candidates
targeting
front
back
eye
indications
company
lead
product
candidate
eye
drops
eye
drop
formulation
phentolamine
mesylate
adrenergic
antagonist
designed
reduce
pupil
size
developed
several
indications
including
dim
light
night
vision
disturbances
mydriasis
presbyopia
ocuphire
second
product
candidate
oral
tablet
designed
inhibit
angiogenesis
inflammation
pathways
relevant
retinal
choroidal
vascular
diseases
diabetic
retinopathy
diabetic
macular
edema
part
strategy
ocuphire
continue
explore
opportunities
acquire
additional
ophthalmic
assets
seek
strategic
partners
development
regulatory
preparation
commercialization
drugs
key
global
markets
please
visit
learn
ocuphire
recent
phase
clinical
trials
information
please
visit
rexahn
pharmaceuticals
rexahn
pharmaceuticals
nasdaqcm
rexn
biotechnology
company
focused
development
innovative
therapies
improve
patient
outcomes
cancers
difficult
treat
additional
information
please
visit
http
statements
statements
contained
press
release
regarding
matters
historical
facts
statements
within
meaning
private
securities
litigation
reform
act
statements
include
limited
statements
concerning
structure
timing
completion
proposed
merger
ocuphire
financing
ocuphire
future
operations
financial
position
revenue
parties
may
actually
achieve
proposed
merger
otherwise
carry
intentions
meet
expectations
projections
disclosed
statements
place
undue
reliance
statements
statements
subject
risks
uncertainties
actual
results
may
differ
materially
expressed
implied
statements
statements
based
upon
rexahn
ocuphire
current
expectations
involve
assumptions
may
never
materialize
may
prove
incorrect
actual
results
timing
events
could
differ
materially
anticipated
statements
result
various
risks
uncertainties
include
without
limitation
risks
associated
timing
closing
proposed
merger
transaction
including
risks
condition
closing
would
satisfied
within
expected
timeframe
closing
proposed
merger
transaction
occur
ii
outcome
legal
proceedings
may
instituted
parties
others
related
merger
agreement
iii
whether
nasdaq
capital
market
continue
list
common
shares
rexahn
following
merger
iv
occurrence
event
change
circumstance
condition
could
give
rise
termination
merger
agreement
v
unanticipated
difficulties
expenditures
relating
proposed
merger
transaction
response
business
partners
competitors
announcement
proposed
merger
transaction
vi
whether
combined
business
rexahn
ocuphire
successful
vii
risks
detailed
rexahn
recent
annual
report
form
fiscal
year
ended
december
subsequent
reports
filed
sec
well
documents
may
filed
rexahn
time
time
sec
including
proxy
statement
prospectus
included
certain
registration
statement
form
file
initially
filed
sec
july
declared
effective
sec
october
statements
contained
press
release
speak
date
made
rexahn
undertakes
obligation
update
statements
reflect
events
occur
circumstances
exist
date
made
rexahn
contact
douglas
swirsky
president
ceo
rexahn
pharmaceuticals
swirskyd
ocuphire
contact
mina
sooch
president
ceo
ocuphire
pharma
msooch
